Author:
Kim Dai Woo,Shin Jonghoon,Lee Chang Kyu,Kim Myungjin,Lee Sohyeon,Rho Seungsoo
Abstract
AbstractGiven that nonadherence is related to subject characteristics and drug tolerance and preserved eye drops tend to be more intolerable than preservative-free ones, we conducted a phase 4, parallel-grouped, investigator-blind, active-control, randomized, multicenter study. A total of 51 patients with intraocular pressure (IOP) ≥ 15 mmHg diagnosed with open-angle glaucoma or ocular hypertension were randomly assigned to the preserved latanoprost group (n = 26) and the preservative-free latanoprost group (n = 25). The efficacy variables were corneal/conjunctival staining grade, Ocular Surface Disease Index (OSDI), adherence at 12 weeks after the first administration; corneal/conjunctival staining grade at 4 weeks; and IOP, tear break-up time (TBUT), and hyperemia score at 4 and 12 weeks. The safety variables included visual acuity and drug tolerance questionnaire results. There was no statistically significant difference in corneal/conjunctival staining grade, OSDI, or TBUT between the groups at 4 and 12 weeks. However, the adherence rate was higher and the hyperemia score was lower in the preservative-free group than in the preserved group. The severity and duration of stinging/burning sensation were lower in the preservative-free group than in the preserved group. Overall, preservative-free latanoprost showed better ocular tolerance assessed by hyperemia scores and stinging/burning symptoms following higher adherence than preserved latanoprost.
Publisher
Springer Science and Business Media LLC
Reference32 articles.
1. Tham, Y. C. et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: A systematic review and meta-analysis. Ophthalmology 121(11), 2081–2090 (2014).
2. Zimmerman, T. J. H. S., Gelb, L., Tan, H. & Kim, E. E. The impact of ocular adverse effects in patients treated with topical prostaglandin analogs: Changes in prescription patterns and patient persistence. J. Ocul. Pharmacol. Ther. 25, 145–152 (2009).
3. Rossi, G. C. M. P. G., Scudeller, L. & Bianchi, P. E. Ocular surface disease and glaucoma: How to evaluate impact on quality of life. J. Ocul. Pharmacol. Ther. 29, 390–394 (2013).
4. Lemij, H. G. H. J. & van der Windt, C. Patient satisfaction with glaucoma therapy: Reality or myth?. Clin. Ophthalmol. Auckl. N.Z. 9, 785–793 (2015).
5. Jaenen, N. B. C., Pouliquen, P., Manni, G., Figueiredo, A. & Zeyen, T. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur. J. Ophthalmol. 86(4), 418–423 (2007).
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献